Foghorn Therapeutics INC Form 4 insider transactions

Thomas J. Lynch Jr., a Director at Foghorn Therapeutics Inc., has acquired stock options granting the right to purchase 28,000 shares.

Stuart Duty, a Director at Foghorn Therapeutics Inc., reported the acquisition of 28,000 stock options with an exercise price of $4.08.

Director Scott Biller of Foghorn Therapeutics Inc. was granted stock options for 28,000 shares.

Neil Gallagher, a Director at Foghorn Therapeutics Inc., reported the acquisition of 28,000 stock options with an exercise price of $4.08.

Michael Mendelsohn, a Director at Foghorn Therapeutics Inc., reported the acquisition of stock options.

Ian F. Smith, a Director at Foghorn Therapeutics Inc., reported the acquisition of stock options on June 24, 2026, as per SEC Form 4 filing.

Director Simba Gill of Foghorn Therapeutics Inc. reported the acquisition of stock options on June 24, 2026, as per SEC Form 4 filing.

Foghorn Therapeutics Director B. Lynne Parshall reported the acquisition of stock options, indicating a potential future stake in the company.

Director Douglas G. Cole reported the acquisition of 28,000 shares of Foghorn Therapeutics Inc. (FHTX) common stock via stock options.

Adrian Gottschalk, CEO and Director of Foghorn Therapeutics, reports significant transfers of company common stock between trusts.

Foghorn Therapeutics Inc.'s Chief Financial Officer, Ryan D. Maynard, was granted 400,000 stock options with an exercise price of $5.75.

Foghorn Therapeutics Inc. CEO Adrian Gottschalk was granted 1,075,000 stock options with a strike price of $5.23, vesting over four years.

Foghorn Therapeutics' Chief People Officer, Carlos Costa, was granted 230,000 stock options with an exercise price of $5.71, vesting over four years.

Foghorn Therapeutics Inc. has granted its Chief Legal Officer, Michael LaCascia, stock options to purchase 295,000 shares of common stock at an exercise price of $5.71 per share.

Foghorn Therapeutics' Chief Medical Officer, Alfonso Quintas-Cardama, was granted 300,000 stock options with a $5.71 exercise price.

Foghorn Therapeutics' Chief Business Officer, Anna Rivkin, was granted 165,000 stock options with an exercise price of $5.71 per share.

Foghorn Therapeutics' Chief Scientific Officer, Steven F. Bellon, was granted 300,000 stock options at an exercise price of $5.71.

Flagship Pioneering entities acquired over 4.4 million warrants in Foghorn Therapeutics, including pre-funded and series warrants with potential price resets, as part of a registered direct offering.

Kristian Humer has resigned as Chief Financial Officer of Foghorn Therapeutics Inc., with the change effective November 14, 2025.

Foghorn Therapeutics Inc. Director Ian F. Smith reported the acquisition of 25,000 stock options with an exercise price of $4.79, exercisable from June 17, 2026.

Foghorn Therapeutics Inc. Director B. Lynne Parshall was granted 25,000 stock options with an exercise price of $4.79 per share, exercisable from June 17, 2026, and expiring on June 16, 2035.

Foghorn Therapeutics Inc. Director Michael Mendelsohn reported the acquisition of 25,000 stock options at an exercise price of $4.79 per share, exercisable from June 17, 2026, as disclosed in a recent SEC Form 4 filing.

Thomas J. Lynch Jr., a Director at Foghorn Therapeutics Inc., has acquired 25,000 stock options with an exercise price of $4.79 per share, as disclosed in a recent SEC Form 4 filing.

Foghorn Therapeutics Inc. Director Simba Gill reported the acquisition of 25,000 stock options with an exercise price of $4.79, exercisable from June 17, 2026, and expiring in 2035.

Foghorn Therapeutics Inc. Director Scott Biller has acquired 25,000 stock options at an exercise price of $4.79, exercisable from June 17, 2026, and expiring on June 16, 2035.

Foghorn Therapeutics Inc. Director Douglas G. Cole was granted 25,000 stock options at an exercise price of $4.79, aligning his interests with shareholder value.

Director Neil Gallagher acquired 50,000 stock options in Foghorn Therapeutics Inc. on May 1, 2025.

Director Stuart Duty acquired 50,000 stock options in Foghorn Therapeutics Inc. on May 1, 2025.

CEO Adrian Gottschalk transferred 300,000 shares of Foghorn Therapeutics stock from his living trust to a grantor retained annuity trust on April 25, 2025.

CEO Adrian Gottschalk transferred 197,906 shares of Foghorn Therapeutics Inc. common stock from a Grantor Retained Annuity Trust to a Living Trust on April 9, 2025.